Stock News

Arena Pharmaceuticals, Inc. (ARNA) Analysts See $-0.64 EPS; MSA Safety (MSA) Covered By 2 Bulls

Analysts expect Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) to report $-0.64 EPS on March, 13.They anticipate $2.24 EPS change or 140.00% from last quarter’s $1.6 EPS. After having $-0.65 EPS previously, Arena Pharmaceuticals, Inc.’s analysts see -1.54% EPS growth. The stock increased 3.41% or $1.31 during the last trading session, reaching $39.71. About 683,594 shares traded or 27.89% up from the average. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) has declined 11.92% since February 11, 2017 and is downtrending. It has underperformed by 28.62% the S&P500.

Among 5 analysts covering MSA Safety Incorporated (NYSE:MSA), 2 have Buy rating, 0 Sell and 3 Hold. Therefore 40% are positive. MSA Safety Incorporated had 14 analyst reports since July 24, 2015 according to SRatingsIntel. The company was maintained on Monday, February 27 by Barrington Research. The stock has “Buy” rating by Stifel Nicolaus on Tuesday, June 14. As per Friday, July 24, the company rating was downgraded by Global Hunter Securities. The stock has “Buy” rating by Stifel Nicolaus on Thursday, August 3. The stock has “Neutral” rating by Robert W. Baird on Monday, October 23. Stifel Nicolaus maintained the stock with “Buy” rating in Wednesday, June 28 report. On Tuesday, April 19 the stock rating was downgraded by Sidoti to “Neutral”. Stifel Nicolaus maintained the shares of MSA in report on Thursday, October 5 with “Buy” rating. The firm has “Neutral” rating given on Tuesday, October 3 by Robert W. Baird. The rating was maintained by Robert W. Baird with “Hold” on Friday, October 20. See MSA Safety Incorporated (NYSE:MSA) latest ratings:

23/10/2017 Broker: Robert W. Baird Rating: Neutral Old Target: $80 New Target: $89 Maintain
20/10/2017 Broker: Robert W. Baird Rating: Hold New Target: $89.0 Maintain
05/10/2017 Broker: Stifel Nicolaus Rating: Buy New Target: $91.0 Maintain
03/10/2017 Broker: Robert W. Baird Old Rating: Outperform New Rating: Neutral Downgrade

Investors sentiment increased to 2.1 in Q3 2017. Its up 0.30, from 1.8 in 2017Q2. It is positive, as 19 investors sold MSA Safety Incorporated shares while 41 reduced holdings. 41 funds opened positions while 85 raised stakes. 25.38 million shares or 0.20% more from 25.32 million shares in 2017Q2 were reported. 3.47M are owned by Blackrock. Commonwealth Of Pennsylvania School Empls Retrmt holds 0.01% or 4,958 shares. Oregon Public Employees Retirement Fund reported 11,609 shares. Picton Mahoney Asset Mngmt holds 0.02% of its portfolio in MSA Safety Incorporated (NYSE:MSA) for 3,400 shares. Sit Inv Assocs holds 19,125 shares or 0.04% of its portfolio. Morgan Dempsey Capital Mgmt Llc accumulated 1.93% or 72,435 shares. Moreover, Cubist Systematic Strategies has 0.02% invested in MSA Safety Incorporated (NYSE:MSA) for 5,216 shares. Anchor Capital Ltd Llc reported 0.07% of its portfolio in MSA Safety Incorporated (NYSE:MSA). Citadel Advisors Llc accumulated 0% or 41,880 shares. Thrivent Fincl For Lutherans has 7,230 shares for 0% of their portfolio. Vanguard Grp Inc holds 3.29M shares. Insight Capital & Mgmt Inc reported 11,940 shares. Assetmark Incorporated invested in 37 shares or 0% of the stock. Envestnet Asset Mngmt invested in 0% or 143 shares. Zacks Invest Mngmt holds 40,687 shares.

The stock increased 0.76% or $0.55 during the last trading session, reaching $73.32. About 122,917 shares traded. MSA Safety Incorporated (NYSE:MSA) has risen 64.52% since February 11, 2017 and is uptrending. It has outperformed by 47.82% the S&P500.

MSA Safety Incorporated develops, manufactures, and supplies safety products that protect people and facility infrastructures in the oil, gas, petrochemical, fire service, construction, utilities, and mining industries worldwide. The company has market cap of $2.79 billion. The firm operates through Americas and International divisions. It has a 33.66 P/E ratio. The Company’s core product offerings include permanently installed fixed gas and flame detection instruments, such as multi-point permanently installed gas detection systems, flame detectors and open-path infrared gas detectors, a laser gas detection technology, replacement components, and related services to detect the presence or absence of various gases in the air.

Since August 30, 2017, it had 0 insider buys, and 6 sales for $3.70 million activity. On Wednesday, September 13 Weber Markus H sold $423,043 worth of MSA Safety Incorporated (NYSE:MSA) or 5,811 shares. Shares for $477,016 were sold by BOVE KERRY M on Tuesday, October 24. On Monday, October 30 Vartanian Nishan J. sold $56,017 worth of MSA Safety Incorporated (NYSE:MSA) or 705 shares. RYAN JOHN T III also sold $2.29M worth of MSA Safety Incorporated (NYSE:MSA) shares.

Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel small molecule drugs for various therapeutic areas in the United States and Switzerland. The company has market cap of $1.56 billion. The company's proprietary investigational clinical programs include etrasimod , which is in Phase IIb evaluation for ulcerative colitis, as well as is in Phase IIa evaluation for dermatologic extraintestinal manifestations in inflammatory bowel disease, pyoderma gangrenosum, and primary biliary cholangitis; ralinepag that is in Phase IIb evaluation to treat pulmonary arterial hypertension; and APD371, which is in Phase IIa evaluation for the treatment of pain associated with Crohn's disease. It currently has negative earnings. It has collaboration agreements with Eisai Inc.; Eisai Co., Ltd.; Axovant Sciences Ltd.; and Boehringer Ingelheim International GmbH.

Among 8 analysts covering Arena Pharmaceuticals (NASDAQ:ARNA), 6 have Buy rating, 0 Sell and 2 Hold. Therefore 75% are positive. Arena Pharmaceuticals had 16 analyst reports since October 28, 2015 according to SRatingsIntel. The firm has “Outperform” rating by Wells Fargo given on Wednesday, January 3. As per Thursday, September 15, the company rating was initiated by FBR Capital. As per Thursday, January 4, the company rating was maintained by Cantor Fitzgerald. The stock of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) earned “Buy” rating by Cantor Fitzgerald on Tuesday, July 11. RBC Capital Markets maintained the shares of ARNA in report on Wednesday, November 11 with “Sector Perform” rating. The firm has “Buy” rating by Cantor Fitzgerald given on Wednesday, November 8. The rating was maintained by Leerink Swann with “Buy” on Wednesday, January 17. The rating was maintained by Leerink Swann with “Buy” on Monday, July 17. Cantor Fitzgerald maintained Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) rating on Wednesday, July 19. Cantor Fitzgerald has “Buy” rating and $3700 target. The company was maintained on Wednesday, October 28 by WallachBeth Capital.

Leave a Reply

Your email address will not be published. Required fields are marked *